M. Obeid

Discipline

Histoire, Philosophie et Sociologie des sciences (1)

Type de document

Articles (14) Recensions (3)

Co-auteur

Date

Source

Mot-clé

Treatment (12) Patients (10) thérapie (9) Therapeutics (9) Patients (9) Human beings (9) Inhibitors (7) Cancer (6) Immunotherapy (6) Immunotherapy (6) maladie (6) maladie (5) cancer (5) Cancer (5) Use (5) Blockades (4) Immunoglobulins (4) Blockade (4) Management (4) besoin (3) gestion (3) anticorps (3) Case (3) Control (3) Autoimmunity (3) Tumors (3) Population (3) Management (3) Liver (3) Immunoglobulin G (3)

Documents écrit par M. Obeid (14) | parle de M. Obeid (0)

Novel targets for immune-checkpoint inhibition in cancer.
M. Borgeaud et al.
A CD64/FcγRI-mediated mechanism hijacks PD-1 from PD-L1/2 interaction and enhances anti-PD-1 functional recovery of exhausted T cells.
V. Joo et al. (2023)
Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial.
G. Stalder et al. (1 janv. 2023)
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.
A. Coukos et al.
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
M. Obeid et al. (1 mai 2022)
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.
S. Boughdad et al.
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
L. Moi et al.
Cardiotoxicité des inhibiteurs de points de contrôle immunitaire utilisés dans le traitement des cancers [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment]
D. Arangalage et al. (3 juin 2020)
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
J. Haanen et al.
COVID-19 and lung cancer: risks, mechanisms and treatment interactions.
A. Addeo et al.
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
F. Martins et al.
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.
A. Horisberger et al. (27 déc. 2018)
A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.
J. Ghosn et al. (22 oct. 2018)
Generating the Abscopal Effect by Combining Proapoptotic Peptides With IL-12-Based Immunotherapy.
F. Martins et al.